What is plasma cell leukaemia?
Plasma cell leukaemia (PCL) is a rare and aggressive blood cancer in which abnormal plasma cells circulate in large numbers in the bloodstream. Plasma cells are a type of white blood cell that normally make antibodies to fight infection.
In plasma cell leukaemia, one faulty plasma cell multiplies out of control, crowds the bone marrow and spills into the blood.
PCL belongs to the same family as multiple myeloma, the more common plasma cell cancer. In myeloma, the abnormal cells mostly stay in the bone marrow. In PCL they also travel in the blood and can settle in organs such as the liver, spleen and lymph nodes.
Experts now define PCL as myeloma with 5% or more abnormal plasma cells in a blood film (Fernandez de Larrea et al., 2021). The previous threshold was 20%.
There are two forms:
- Primary PCL appears from the start, in a person not previously known to have myeloma.
- Secondary PCL develops later, in someone who already has myeloma, usually after several treatments.
PCL develops in only a small share of people with myeloma, about 0.5-4% (Jung and Lee, 2022). It needs urgent, intensive treatment. Modern drug combinations followed by a stem cell transplant have improved survival, but the outlook remains poorer than in myeloma (Musto et al., 2025).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Plasma cell neoplasm with circulating plasma cells |
| Definition | Myeloma with 5% or more circulating plasma cells in the blood |
| Forms | Primary (at diagnosis) and secondary (after myeloma) |
| How common | 0.5-4% of people with myeloma |
| Typical age | Usually 50s-60s; often a little younger than myeloma |
| Main features | Anaemia, kidney problems, high calcium, organ enlargement |
| Main treatment | Intensive drug combinations, stem cell transplant, maintenance |
| Median survival | About 2 years without transplant; 3 years or more with transplant |
| Outlook | Guarded; it is classed as ultra-high-risk disease |
2. Types
| Type | Description | Notes |
|---|---|---|
| Primary PCL | Diagnosed at first presentation | Most of the published treatment research concerns this form |
| Secondary PCL | Arises in established myeloma | Usually after several lines of treatment; outlook is especially poor |
How the definition has changed
| Period | Definition |
|---|---|
| Older definition | At least 20% plasma cells in the blood, or more than 2 x 10^9/L |
| IMWG definition from 2021 | 5% or more plasma cells in a blood smear, in someone who otherwise meets criteria for myeloma |
The International Myeloma Working Group (IMWG) lowered the threshold because people with 5% or more circulating plasma cells did as badly as those meeting the older definition (Fernandez de Larrea et al., 2021).
How PCL differs from myeloma
| Feature | Plasma cell leukaemia | Multiple myeloma |
|---|---|---|
| Plasma cells in the blood | Many | Few or none |
| Organ involvement | Liver, spleen, lymph nodes and other sites more often | Less common |
| Kidney failure | More frequent | Less frequent |
| Bone lesions | Sometimes less prominent | Common |
| High-risk genetic changes | Common | Less common |
| Speed of illness | Rapid | Usually slower |
3. Causes and risk factors
The cause of PCL is unknown. It is not caused by lifestyle and is not passed on in families.
| Factor | Notes |
|---|---|
| Age | Mostly affects people in later middle age |
| Existing myeloma | Risk factor for secondary PCL |
| Genetic changes in the cancer cells | Not inherited; arise in the plasma cells themselves |
Genetic changes in the cancer cells
| Change | Notes |
|---|---|
| t(11;14) | Common in PCL; may respond to venetoclax |
| t(4;14), t(14;16) | High-risk changes |
| Deletion of 17p (TP53) | Associated with poorer outlook |
| Gain of 1q | Associated with poorer outlook |
| Complex karyotype | Many changes at once |
These changes are tested in the cancer cells, using FISH or other genetic methods, to help plan treatment. The association of t(11;14) with PCL makes BCL2 inhibitors such as venetoclax a possible targeted option (Gong et al., 2024).
4. How does it look
In the blood
| Test | Typical finding |
|---|---|
| Blood count | Low haemoglobin and platelets; raised white cell count in some |
| Blood film | Plasma cells visible under the microscope |
| Flow cytometry | Counts and characterises the abnormal plasma cells |
| Paraprotein | Abnormal antibody (M protein) in blood or urine; sometimes only light chains |
In the bone marrow
The marrow is often packed with abnormal plasma cells. A bone marrow biopsy confirms the diagnosis and provides cells for genetic testing.
On scans
| Test | What it shows |
|---|---|
| Whole-body low-dose CT | Bone damage |
| MRI | Marrow and spinal involvement |
| PET-CT | Disease outside the bones, such as in soft tissue or organs |
5. Symptoms
Symptoms often appear quickly, over weeks.
Common symptoms
- Tiredness and breathlessness from anaemia
- Bone pain, often in the back or ribs
- Frequent infections due to low normal antibodies
- Bruising or bleeding from low platelets
- Weight loss and fevers
Less common symptoms
| Symptom | Possible cause |
|---|---|
| Thirst, confusion, constipation | High calcium |
| Passing less urine, swelling | Kidney damage |
| Swollen abdomen or discomfort | Enlarged liver or spleen |
| Enlarged lymph nodes | Spread to nodes |
| Headache, confusion, nerve problems | Spread to the brain or its lining, which is rare |
| Lumps under the skin | Plasma cell tumours outside the bones |
When to seek urgent help
Seek urgent medical attention for fever with low blood counts, confusion, severe back pain with weakness or numbness in the legs, or passing very little urine.
6. Diagnosis
| Test | Purpose |
|---|---|
| Full blood count and blood film | Detects circulating plasma cells |
| Flow cytometry of blood | Measures the percentage of plasma cells |
| Serum protein tests and free light chains | Measure the abnormal antibody |
| Kidney function and calcium | Detect organ damage |
| LDH and beta-2 microglobulin | Reflect disease bulk and risk |
| Bone marrow biopsy with FISH | Confirms diagnosis and detects genetic changes |
| Whole-body imaging | Bone and extramedullary disease |
| Lumbar puncture | If there are nervous system symptoms |
| Heart and lung assessment | Before intensive treatment |
Staging and risk
PCL is not staged like solid cancers. It is regarded as ultra-high-risk plasma cell disease from the start (Fernandez de Larrea et al., 2021). The team also assesses fitness for transplant, kidney function and genetic risk.
7. Treatment
Because PCL progresses rapidly, treatment should start immediately after diagnosis (Jung and Lee, 2022). Care is best given in a specialist haematology centre, and patients are encouraged to join clinical trials.
Phases of treatment
| Phase | Purpose | Typical approach |
|---|---|---|
| Induction | Rapidly reduce the disease | Combinations including a proteasome inhibitor (bortezomib or carfilzomib), an immunomodulatory drug (lenalidomide), dexamethasone and often an anti-CD38 antibody (daratumumab) |
| Stem cell collection | Harvest the patient’s own stem cells | After a good response |
| Autologous stem cell transplant | High-dose melphalan followed by return of stem cells | Recommended for fit patients; sometimes done twice (tandem) |
| Allogeneic transplant | Donor stem cells | Considered in selected younger patients, usually within trials |
| Maintenance | Delay relapse | Lenalidomide, with or without a proteasome inhibitor |
Maintenance after transplant may reduce early relapses (Jung and Lee, 2022). In recent trials, between about 7 and 9 in 10 patients responded to treatment, and median overall survival ranged from about 2 to 3 years (Gong et al., 2024).
A typical first year of treatment
| Months | What usually happens |
|---|---|
| Week 1 | Diagnosis, urgent start of treatment, kidney and calcium care |
| Months 1-4 | Induction cycles, often partly as an inpatient at first |
| Months 4-5 | Stem cell collection |
| Months 5-7 | Autologous transplant, with 2-4 weeks in hospital |
| Months 7-12 | Recovery, then maintenance treatment begins |
Targeted and newer treatments
| Treatment | Notes |
|---|---|
| Venetoclax | Targets BCL2; an option for disease with t(11;14) |
| Bispecific antibodies | Being studied, mainly at relapse |
| CAR T-cell therapy | Being studied in PCL |
| Intensive chemotherapy combinations (for example VTD-PACE) | Used for rapid disease control in some centres |
Supportive care
| Problem | Treatment |
|---|---|
| Kidney damage | Fluids, rapid control of the disease, sometimes dialysis |
| High calcium | Fluids, bisphosphonates or denosumab |
| Infection risk | Antibiotic and antiviral prevention, vaccinations, immunoglobulin replacement |
| Bone pain and fractures | Painkillers, bone-strengthening drugs, radiotherapy, surgery |
| Blood clots | Preventive blood thinners with some drugs |
| Tumour lysis syndrome | Fluids and drugs to protect the kidneys at the start of treatment |
Side effects
| Treatment | Possible side effects |
|---|---|
| Bortezomib | Nerve damage (tingling, numbness), shingles risk |
| Lenalidomide | Low blood counts, clots, rash, diarrhoea |
| Daratumumab | Infusion reactions, infections |
| Dexamethasone | Mood changes, sleep problems, high blood sugar |
| High-dose melphalan and transplant | Mouth ulcers, nausea, severe infection risk for 2-3 weeks |
8. Outlook (prognosis)
PCL remains the most aggressive plasma cell cancer (Musto et al., 2025). The European Myeloma Network reports that people treated with modern drug combinations who cannot have a transplant may survive a median of up to 2 years. Those who do have transplant procedures may survive a median of 3 years or more.
| Factor | Effect on outlook |
|---|---|
| Fitness for transplant | Transplant is linked with longer survival |
| Deep response to induction | Better outcome |
| High-risk genetic changes | Poorer outcome |
| Secondary PCL | Poorer outlook than primary PCL |
| Kidney failure or high LDH | Poorer outlook |
| Access to clinical trials | Offers newer treatments |
These are averages. Some patients live much longer, and outcomes are improving as new treatments become available.
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Blood tests every 4-8 weeks | Paraprotein, light chains, blood counts and kidney function |
| Bone marrow tests | Check response and measurable residual disease |
| Imaging | When symptoms or tests suggest progression |
| Vaccination review | Re-vaccination after transplant |
| Monitoring for side effects | Nerve damage, clots, infections, second cancers |
10. Living with plasma cell leukaemia
- Report fever promptly, especially during treatment, as infections can become serious quickly
- Drink plenty of fluids to protect your kidneys, unless told otherwise
- Avoid anti-inflammatory painkillers such as ibuprofen, which can harm the kidneys
- Keep active within your limits; physiotherapists can advise on safe exercise with bone disease
- Look after your teeth, particularly if you receive bone-strengthening drugs
- Ask about clinical trials at diagnosis and at relapse
- Seek support from myeloma charities, which also support people with PCL
For family members and carers
- Learn the warning signs of infection and when to call the hospital
- Help with transport to frequent appointments
- Look after your own health, and ask about carer support services
- Keep a shared list of medicines, appointments and contact numbers
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is plasma cell leukaemia the same as myeloma? | It is closely related but more aggressive, with many cancer cells in the blood |
| Is it the same as other leukaemias? | No; it is a plasma cell cancer, treated with myeloma drugs |
| Can it be cured? | Cure is rare, but treatment can control it, sometimes for years |
| Will I need a stem cell transplant? | It is recommended if you are fit enough |
| Why does treatment start so quickly? | The disease can damage organs within weeks |
| Is it inherited? | No; my children do not need special tests |
| What is measurable residual disease? | A highly sensitive test showing whether tiny amounts of cancer remain after treatment |
| Will I lose my hair? | Not with most myeloma drugs, but usually after high-dose melphalan, temporarily |
| Can I work during treatment? | Some people can, but many need time off, especially around transplant |
12. Questions to ask your care team
- Do I have primary or secondary PCL?
- What genetic changes do the cancer cells have?
- Which treatment combination do you recommend, and why?
- Am I suitable for a stem cell transplant?
- Is there a clinical trial I could join?
- How can I reduce my risk of infection?
- What support is available for me and my family?
- Who should I call out of hours if I feel unwell?
- How will we know whether the treatment is working?
Resources
- Fernandez de Larrea, C. et al. (2021) ‘Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage’, Blood Cancer Journal, 11(12), 192.
- Gong, Z. et al. (2024) ‘Current status on management of primary plasma cell leukemia’, Current Oncology Reports, 26(9), pp. 1104-1112.
- Jung, S.H. and Lee, J.J. (2022) ‘Update on primary plasma cell leukemia’, Blood Research, 57(S1), pp. 62-66.
- Musto, P. et al. (2025) ‘European Myeloma Network Group review and consensus statement on primary plasma cell leukemia’, Annals of Oncology, 36(4), pp. 361-374.
- National Cancer Institute (2026) Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.